CURE Pharmaceutical Welcomes Raymond Watt to Board
CURE Pharmaceutical, known for its revolutionary sublingual delivery systems, has announced the exciting appointment of Raymond Watt to its Board of Directors.
Introducing Raymond Watt
Raymond Watt, originally from South Africa and currently based in California, brings extensive expertise to CURE. He has served as Chairman Emeritus of YPO.org, a global organization for chief executives, and is currently the Chairman of Rimar.ai, a data analytics company. Rimar.ai develops advanced quantitative models tailored for hedge fund operations.
Transforming Access to Treatments
Watt expressed his enthusiasm for joining CURE, stating, “CURE has revolutionized access to vital treatments, eliminating the need for needles and bulky storage, which makes essential medications accessible worldwide.” He emphasizes his commitment to scaling this transformative delivery system with selected partners. This reflects CURE’s mission to innovate how healthcare products are administered, greatly improving the patient experience.
Collaboration with CURE Leadership
Watt will work closely with CURE's CEO, Robert Davidson, the inventor behind the patented technology utilized in CURE’s systems. Davidson remarked, “Raymond embodies our culture and values. His passion for using business as a force for good, combined with his exceptional leadership and strategic thinking, aligns perfectly with CURE’s mission.” This synergy between Watt and Davidson is expected to foster significant advancements for the company.
Strategic Goals Ahead
In the upcoming year, Watt's primary focus will be to develop global strategic partnerships and create scalable delivery solutions. His role will be pivotal in CURE’s dedication to delivering essential treatments to communities in need, enhancing the reach of their innovative solutions.
About CURE Pharmaceutical
CURE Pharmaceutical has made significant strides with a patented sublingual and buccal delivery technology that allows for rapid absorption directly into the bloodstream. This method bypasses first-pass metabolism, improving patient compliance and enabling precision dosing. CUREfilm® can accommodate most active ingredients up to 200mg, is stable at room temperature, and does not require refrigeration. These advancements signify CURE's commitment to providing effective healthcare solutions worldwide.
Contact Information
For media inquiries, please reach out to:
Patricia Hess
Phone: +1 805-824-0410
Frequently Asked Questions
What is the significance of Raymond Watt's appointment?
Raymond Watt's experience in leadership and data analytics will enhance CURE's strategic vision and partnership development.
What are CURE's main innovations?
CURE specializes in sublingual delivery systems that improve the effectiveness and accessibility of medications without the need for injections.
How does CURE’s technology benefit patients?
CURE's technology allows for rapid drug absorption and precision dosing, improving adherence and overall treatment efficiency.
What future initiatives will CURE Pharmaceutical pursue?
CURE aims to establish global partnerships and bolster the international presence of its innovative delivery systems.
How can I learn more about CURE Pharmaceutical?
You can visit CURE Pharmaceutical's official website for comprehensive information about their products and innovations.
